<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Velmanase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Velmanase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Velmanase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="140826" href="/d/html/140826.html" rel="external">see "Velmanase alfa: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="141000" href="/d/html/141000.html" rel="external">see "Velmanase alfa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57885722"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions including anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Patients treated with velmanase alfa have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during velmanase alfa administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue velmanase alfa immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to velmanase alfa may be considered.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57971591"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lamzede</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57889357"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F57984638"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Consider premedication with antihistamines, antipyretics, and/or corticosteroids.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e6d45fc-a96f-4566-9e64-503ace63375c">Alpha-mannosidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alpha-mannosidosis: IV:</b> Dosing based on actual body weight: 1 mg/kg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29846843','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29846843','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If 1 or more doses are missed and the next scheduled dose is ≥3 days away, restart treatment as soon as possible, then resume usual dosing schedule. If 1 or more doses are missed and next scheduled dose is within 3 days, only administer next scheduled dose, then resume usual dosing schedule.</p></div>
<div class="block dora drugH1Div" id="F57984640"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F57984641"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F57984646"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity or infusion-associated reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate reactions</i>
<i>: </i>Initiate appropriate medical treatment and interrupt infusion for 15 to 30 minutes, then reinitiate infusion at 25% to 50% of the recommended rate. Monitor and follow appropriate next steps based on symptoms:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If symptoms subside following interruption or decreased infusion rate</i>
<i>: </i>Resume infusion at 25% to 50% recommended rate; if tolerated, increase infusion rate in increments of 25% of recommended rate until recommended infusion rate is reached.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If symptoms persist following interruption or decreased infusion rate</i>
<i>:</i> Stop infusion and monitor; if symptoms persist, discontinue infusion and consider reinitiating infusion within 7 to 14 days at 25% to 50% of recommended rate with appropriate pretreatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe reactions (eg, anaphylaxis</i>
<i>):</i> Discontinue therapy immediately and initiate appropriate medical treatment. Consider risks and benefits of therapy readministration. If therapy continued, consider desensitization measures (for hypersensitivity reactions) and/or rechallenging using slower infusion rates. If slower infusion rates are tolerated, may increase to recommended rates.</p></div>
<div class="block doe drugH1Div" id="F57984639"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57987160"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140826" href="/d/html/140826.html" rel="external">see "Velmanase alfa: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e09c756-86c6-49c0-a8f2-ef7f96208132">Alpha-mannosidosis, noncentral nervous system manifestations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alpha-mannosidosis, noncentral nervous system manifestations: Note:</b> Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids to decrease risk of hypersensitivity and infusion-associated reactions (IARs); use actual body weight for dosing:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV infusion: 1 mg/kg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32905047','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32905047','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypersensitivity reactions or IARs:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate: Hold infusion for 15 to 30 minutes and initiate appropriate medical care; then restart infusion at 25% to 50% of recommended rate. Monitor and follow appropriate next steps based on symptoms:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If symptoms subside after holding the infusion or decreasing the infusion rate</i>
<i>: </i>Resume infusion at 25% to 50% of recommended rate; if tolerated, increase infusion rate in increments of 25% of recommended rate until recommended infusion rate is reached.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If symptoms persist after holding the infusion or decreasing the infusion rate</i>
<i>:</i> Stop infusion and monitor; if symptoms persist, discontinue infusion and consider reinitiating infusion within 7 to 14 days at 25% to 50% of recommended rate with appropriate pretreatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe: Discontinue infusion immediately and administer appropriate medical treatment. Consider risks and benefits of therapy readministration. If therapy is continued, consider desensitization measures (for hypersensitivity reactions).</p></div>
<div class="block dorp drugH1Div" id="F57987165"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F57987166"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58359561"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with velmanase alfa may commonly experience <b>hypersensitivity reaction</b>, including <b>anaphylaxis</b> and <b>severe hypersensitivity reaction</b> requiring medical treatment. Symptoms may include cyanosis, hypotension, emesis, urticaria, <b>erythema of skin,</b>
<b>facial swelling</b>, <b>fever</b>, and tremor.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immediate allergic hypersensitivity reactions (eg, anaphylaxis) are typically IgE-mediated; delayed-type reactions may be T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34502086','lexi-content-ref-EMA.1','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34502086','lexi-content-ref-EMA.1','lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of anti–velmanase alfa-tycv antibodies (anti-drug antibodies)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher infusion rates</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reaction</b>, including <b>fever</b>, chills, <b>erythema of skin,</b> vomiting, <b>cough</b>, urticaria, <b>skin rash</b>, and <b>conjunctivitis</b>, have been reported with velmanase alfa.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; occurs during or shortly after infusion; first or subsequent reactions may occur several weeks into therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36849760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36849760'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of anti–velmanase alfa-tycv antibodies (anti-drug antibodies)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher infusion rates</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57905657"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, excoriation of skin, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis, upper abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, Henoch-Schönlein purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial swelling, hypersensitivity reaction (including anaphylaxis and severe hypersensitivity reaction), infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (including neutralizing antibodies)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, headache, hyperthermia, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, eye pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, oropharyngeal pain, rhinitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F57885726"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F57971592"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lamzede: Velmanase alfa-tycv 10 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F57971590"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57989946"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Lamzede Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $5,040.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57984647"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Do not shake syringe(s). Consider premedication with antihistamines, antipyretics, and/or corticosteroids. Administer via infusion set equipped with pump and low protein binding, 0.2 micron in-line filter. To control protein load, rate of administration is dependent on patient weight:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Actual body weight &lt;50 kg</i>
<i>:</i> Administer over at least 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Actual body weight ≥50 kg</i>
<i>:</i> Maximum infusion rate: 25 mL/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Following administration of last syringe, replace dosage syringe with 20 mL syringe filled with NS; continue infusion of 10 mL NS to infuse remaining dose in infusion set.</p></div>
<div class="block admp drugH1Div" id="F57987168"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer in setting with medical equipment readily available for the management of anaphylaxis or infusion-associated reactions. Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion: Use low protein binding, 0.2-micron, inline filter; do not shake syringe(s); administration rate based on weight:</p>
<p style="text-indent:-2em;margin-left:4em;">Weight &lt;50 kg: Administer over ≥60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight ≥50 kg: Maximum infusion rate: 25 mL/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Following administration of last syringe, replace dosage syringe with 20 mL syringe filled with NS; continue infusion of 10 mL NS to infuse remaining dose in infusion set.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>: If one or more doses are missed and the next scheduled dose is ≥3 days away, restart treatment as soon as possible. If one or more doses are missed and the next scheduled dose is within 3 days, administer next dose as scheduled.</p></div>
<div class="block use drugH1Div" id="F57885725"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alpha-mannosidosis:</b> Treatment of noncentral nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.</p></div>
<div class="block mst drugH1Div" id="F57984623"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Velmanase alfa may be confused with velaglucerase alfa.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57922705"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57922702"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F57984625"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for 14 days after the last dose of velmanase alfa.</p></div>
<div class="block pri drugH1Div" id="F57984626"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to velmanase alfa may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F57984627"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if velmanase alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57984650"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy status in patients who can become pregnant (prior to treatment initiation); hypersensitivity or infusion-related reactions.</p></div>
<div class="block pha drugH1Div" id="F57984633"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Velmanase alfa binds to extracellular mannose-6-phosphate receptors and is transported to lysosomes, where it provides an exogenous source of alpha mannosidase. Alpha mannosidase degrades mannose-containing oligosaccharides; lack of this enzyme leads to the accumulation of mannose-rich oligosaccharides in tissue, which causes clinical symptoms associated with alpha-mannosidosis lysosomal disease (Borgwardt 2018; manufacturer’s labeling).</p></div>
<div class="block phk drugH1Div" id="F57984634"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 276 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 33.6 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847720"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lamzede</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29846843">
<a name="29846843"></a>Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. <i>J Inherit Metab Dis</i>. 2018;41(6):1215-1223. doi:10.1007/s10545-018-0185-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/29846843/pubmed" id="29846843" target="_blank">29846843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34502086">
<a name="34502086"></a>de la Fuente M, Lombardero L, Gómez-González A, et al. Enzyme therapy: current challenges and future perspectives. <i>Int J Mol Sci</i>. 2021;22(17):9181. doi:10.3390/ijms22179181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/34502086/pubmed" id="34502086" target="_blank">34502086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.1">
<a name="EMA.1"></a>European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). <i>Guideline on immunogenicity assessment of therapeutic proteins</i>. May 18, 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/EMA.1/pubmed" id="EMA.1" target="_blank">EMA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA), U.S. Department of Health and Human Services. <i>Guidance for industry: immunogenicity assessment for therapeutic protein products</i>. August 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/FDA.1/pubmed" id="FDA.1" target="_blank">FDA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36849760">
<a name="36849760"></a>Guffon N, Konstantopoulou V, Hennermann JB, et al. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: a phase 2, open label, multicenter study. <i>J Inherit Metab Dis</i>. 2023;46(4):705-719. doi:10.1002/jimd.12602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/36849760/pubmed" id="36849760" target="_blank">36849760</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lamzede (velmanase alfa) [prescribing information]. Parma, Italy: Chiesi Farmaceutici S.p.A.; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32905047">
<a name="32905047"></a>Santoro L, Zampini L, Padella L, et al. Early biochemical effects of velmanase alfa in a 7-month-old infant with alpha-mannosidosis. <i>JIMD Rep</i>. 2020;55(1):15-21. doi:10.1002/jmd2.12144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velmanase-alfa-drug-information/abstract-text/32905047/pubmed" id="32905047" target="_blank">32905047</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 140819 Version 29.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
